Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)
Status:
Recruiting
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
This study is an open-label, parallel, 2-cohort, multicenter, investigator-initiated Phase 2
trial to evaluate the efficacy and safety of binimetinib in patients with advanced or
recurrent low-grade glioma or pancreatic cancer harboring BRAF fusion/rearrangement.